1. Home
  2. Exits
  3. AmbioPharm

AmbioPharm is a peptide manufacturing business serving a range of pharmaceutical, biotechnology, and research organizations. It also has a pipeline of proprietary generic peptide products. Corden acquired AmbioPharm in 2026.

Latest news

GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
June 9, 2026
GT Medical Announces Breakthrough Brain Cancer Survival
May 30, 2026
CordenPharma to Acquire AmbioPharm to Expand Global Peptide API Capacity
May 27, 2026
Olympus to Acquire BioProtect to Expand Its Portfolio of Urological Technologies and Address Prostate Cancer
May 26, 2026
MVM invests in Neurent Medical
February 11, 2026
Proverum receives FDA approval for the ProVee System – the first of a new generation of prostatic urethral stents for treatment of BPH
December 9, 2025
MVM invests in Avanzanite
November 18, 2025
GT Medical Technologies’ trial demonstrates a >50% reduction in the risk of brain tumor recurrence or death compared with standard of care
October 21, 2025
Boston Scientific agrees to acquire Nalu Medical
October 17, 2025
MVM invests in Proverum
August 25, 2025
View all